Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. The cancer in CRPC no longer responds to hormonal therapy, which include testosterone-lowering treatments. Hormone therapy, also known as androgen deprivation therapy (ADT), reduces testosterone levels in the body significantly. The testosterone levels are reduced to the extent that they are comparable to the men, whose testicles have been surgically removed.
Castration is a colloquial term for the surgical removal of the testes. Low testosterone levels typically slower the progression of prostate cancer. However, in men with castrate-resistant prostate cancer, despite a reduction in testosterone, the cancer progresses. The cancer can be diagnosed by measuring the levels of prostate specific antigen (PSA) in the blood. PSA is a protein produced by prostate cancer cells.
Alternative hormonal therapies that include medications such as Abiraterone (Zytiga) and Enzalutamide (Xtandi), chemotherapy, and immunotherapy are some of the potential treatments for castrate-resistant prostate cancer.
Global Castrate-resistant Prostate Cancer Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 182 million cases and 3.95 million deaths due to coronavirus disease (COVID-19) were reported till July 2, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Castrate-resistant Prostate Cancer Treatment
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Many countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products. Delays and cancellations of cancer treatments, as well as other precautions taken to reduce the risk of exposure to the coronavirus (COVID-19), have created a massive backlog in oncology care and research. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global castrate-resistant prostate cancer market during the forecast period. For instance, according to the European Society for Medical Oncology (ESMO) Virtual Congress 2020, a study was conducted in which responses were gathered from oncology centers in 18 different countries in Europe. Overall, 60.9% of oncology centers’ clinical activity was reduced during the pandemic's peak, while around two-thirds accounting for 64.2% cited under-treatment as a major concern, and 37% expected significant reductions in clinical trials by the end of 2020.
The global castrate-resistant prostate cancer market is estimated to be valued at US$ 9.5 Bn in 2021, and is expected to exhibit a CAGR of 8.2% over the forecast period (2021-2028).
|Base Year:||2020||Market Size in 2021:||US$ 9.5 Bn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||8.2%||2028 Value Projection:||US$ 16.4 Bn|
Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Figure 1: Global Castrate-resistant Prostate Cancer Market Share (%) Analysis, By Therapy Type, 2021
The prevalence of prostate cancer is the major factor that is expected to drive growth of the global castrate-resistant prostate cancer market over the forecast period.
The increasing prevalence of prostate cancer is expected to bolster growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, according to the Global Cancer Observatory report 2018, there were 1,276,106 new cases of prostate cancer reported, resulting in 358,989 deaths (3.8% of all deaths caused by cancer in men) worldwide.
Research and Development activities
The increasing number of clinical trials for the treatment of castrate-resistant prostate cancer is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on February 8, 2021, Janssen Pharmaceutical NV, a subsidiary of Johnson & Johnson, presented its findings from the Phase 3 ACIS Study in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of ERLEADA (apalutamide) and ZYTIGA (abiraterone acetate) at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium. The ACIS study met its primary goal of reducing the time to radiographic progression or death in patients with mCRPC.
Global Castrate-resistant Prostate Cancer Market – Regional Analysis
On the basis of region, the global castrate-resistant prostate cancer market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global castrate-resistant prostate cancer market over the forecast period, owing to increasing approvals of product applications. For instance, on May 19 2020, the U.S. Food and Drugs Administration (FDA) approved olaparib (LYNPARZA), developed by AstraZeneca, a global biopharmaceutical company, for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), which had progressed following prior treatment with enzalutamide or abiraterone.
Moreover, owing to increasing product approvals by European regulatory authorities, Europe is expected to witness a significant growth in the global castrate-resistant prostate cancer market over the forecast period. For instance, on March 30, 2020, European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), for marketing in the European Union (EU). The drug, was co-developed by Orion Corporation and Bayer AG in 2019, and is indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease.
Figure 2: Global Castrate-resistant Prostate Cancer Market Value (US$ Bn), by Region, 2021
Global Castrate-resistant Prostate Cancer Market – Competitive Landscape
Major players operating in the global castrate-resistant prostate cancer market include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to testosterone-lowering treatments. Symptoms of mCRPC include: difficulty urinating, pain while passing urine, or blood in the urine, weight loss and shortness of breath. Hormonal therapies are used to treat CRPC such as abiraterone (Zytiga) with corticosteroids inhibit the chemical production of testosterone throughout the body. Zytiga is used in conjunction with prednisone, a powerful anti-inflammatory medication. Other treatments for CRPC include chemo and immunotherapies.
Market players are focused on raising awareness campaigns related to prostate cancer, which is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on June 17, 2021, patient organization ZERO and Bayer AG, a global life sciences company, collaborated to launch 'We're Not Gonna Take It', a national prostate cancer education program. The campaign encourages men to get screened for prostate cancer and to learn more about risk factors such as family history and elevated prostate-specific antigen (PSA) levels.
Moreover, market players are focusing on product launches and approvals to strengthen their position in the global castrate-resistant prostate cancer market. For instance, on July 30 2019, Bayer AG, a global enterprise, announced that the U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
Furthermore, market players are focusing on research and development activities for the treatment of castrate-resistant prostate cancer, which is expected to drive growth of the global castrate-resistant prostate cancer market. For instance, on April 10 2021, Cardiff Oncology Inc., a clinical-stage biotechnology company in collaboration with scientists at the Massachusetts Institute of Technology's Center for Precision Cancer Medicine (MIT), announced that new gene signature and mechanistic analyses from its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, April, 2021.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.